Dimensional Fund Advisors LP Sells 60,194 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Dimensional Fund Advisors LP lowered its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 31.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 129,062 shares of the biotechnology company’s stock after selling 60,194 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Enanta Pharmaceuticals were worth $1,674,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in Enanta Pharmaceuticals during the second quarter valued at $35,000. State Board of Administration of Florida Retirement System bought a new position in Enanta Pharmaceuticals during the first quarter valued at $118,000. Virtu Financial LLC bought a new position in Enanta Pharmaceuticals during the first quarter valued at $191,000. Quest Partners LLC lifted its position in Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 7,287 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ENTA. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Enanta Pharmaceuticals in a research report on Thursday. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. JMP Securities restated a “market outperform” rating and issued a $22.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th. One analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Insider Buying and Selling

In related news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the transaction, the insider now owns 21,717 shares of the company’s stock, valued at $370,926.36. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 13.64% of the stock is currently owned by insiders.

Enanta Pharmaceuticals Trading Up 3.9 %

Enanta Pharmaceuticals stock opened at $11.04 on Friday. The firm has a 50-day moving average price of $11.98 and a 200-day moving average price of $13.24. The firm has a market capitalization of $233.94 million, a PE ratio of -2.03 and a beta of 0.58. Enanta Pharmaceuticals, Inc. has a 12-month low of $8.08 and a 12-month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. The firm had revenue of $17.97 million during the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The business’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the business earned ($1.27) EPS. As a group, sell-side analysts predict that Enanta Pharmaceuticals, Inc. will post -5.3 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.